# Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

> **NCT00683657** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 93 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Saxagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00683657
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2015-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00683657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00683657, "Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00683657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*